Federal and state cases for prescription drugs Reglan and generic metoclopramide litigation are being filed by plaintiff's suffering with a movement disorder- Tardive Dyskinesia.  Reglan side effect claims continue to be filed in multiple jurisdictions.  States courts currently hearing the cases are Pennsylvania, New Jersey and California. The Supreme Court of the United States will decide later this year, if there is or is not federal preemption of the state law claims in torts for the generic drug manufacturer's warning labels.

Philadelphia is one of the first courts to decide to consolidate the increasing number of cases to conserve the judicial resources in hearings and trials. As the plaintiff's cases proceed with scheduled trial dates, there has been an emphasis on the due diligence of Reglan injury lawyers to execute these cases in a timely and efficient manner. The East and West coast states have followed Pennsylvania's protocol in consolidating the litigation. Reglan side effect claims are serious and the litigation will be time-consuming.

The United States Supreme Court will hear and decide later this year if there is preemption for generic drug manufacturers in regards to warnings on their labels. The legal issue is, "Are generic drug manufacturers equally liable to warn consumers of the side effects, no different than the name brand drug manufacturers?"  Although the defense of the generic drug manufacturer's is, the law currently prevents the generic prescription labels to be modified to read any different than those required by the FDA guidelines on the brand name manufacturer's warning labels.